The high-fat-fed/low-dose streptozotocin-treated (STZ) rat has shown to be a good preclinical model of late-stage T2D exacerbating the metabolic disturbances such as dyslipidemia and insulin resistance observed in high-fat diet models [8, 9] but also adding hyperglycemia and low endogenous insulin levels to the disease model [10, 11]. Here, INS is linked to type 2 diabetes mellitus.